PTC Therapeutics, Inc. (PTCT) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 75
- Profitability 100
- Business Quality 60
- Balance Sheet 40
- Cash Flow 60
Why this rating?
Health 72/100 — High Quality
A usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
Company overview
PTC Therapeutics, Inc. (PTCT) is a Biotechnology company in the Healthcare sector. Compound Radar rates PTC Therapeutics, Inc. 72/100 (High Quality) due to solid business quality, strong revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Strong
- Balance Sheet Stretched
- Valuation Fair
Financial highlights
Valuation
- Forward P/E 27.52
- EV/Revenue 6.52
Profitability
- Revenue Growth 101.5%
- Gross Margin 50.0%
- Operating Margin 41.3%
- Net Margin -3.8%
Financial strength
- Cash $2.23B
- Debt $3.02B
- Net Cash $-788.82M
- Free Cash Flow $411.18M
- Current Ratio 3.39
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks PTC Therapeutics, Inc. (PTCT).